Table 1.

Antiproliferative Activity of Coumarin-based Triazole Derivatives 4^a

R (4, IC50, μM)	SKBr3b	MCF-7b	MDA-MB-468LNc	MDA1986c	JMARc	PC3- MM2d	LNCaPd
Ph (4a)	0.94±0.02a	1.33±0.13a	1.10±0.21	1.50±3.40	2.30±0.40	2.69	4.72±0.71
Bn (4b)	0.99±0.08	1.08±0.00	2.40	1.60±0.21	2.10±0.23	9.8±13.5	15.5±8.75
4-ClC6H5 (4c)	0.58±0.03	2.04±0.25	0.81±0.15	0.18±0.11	0.43±0.38	2.79±0.49	2.45±0.47
4-BrC6H5 (4d)	1.38±0.05	5.07±1.86	2.80±0.50	2.90±0.33	3.60±0.63	3.81±4.99	15.2±9.19
4-MeC6H5 (4e)	1.08±0.05	1.38±0.07	4.00±1.92	0.29	3.64	>100	>100
3-ClC6H5 (4f)	0.71±0.14	1.14±0.18	4.60	6.40	6.40	3.90±5.11	13.3±11.9
4-ClBn (4g)	1.14±0.19	1.44±0.31	2.20±0.30	1.70±0.52	1.70±0.20	3.67±1.38	4.65±0.71
4-BrBn (4h)	0.73±0.01	1.36±0.08	2.10±0.60	2.00±0.50	1.60±0.31	3.80±1.42	4.96±0.67
4-MeBn (4i)	1.21±0.07	1.50±0.19	2.40±0.25	1.50±0.20	1.80±0.95	7.32±5.44	7.24±1.02
4-MeOBn (4j)	1.31±0.20	1.42±0.14	3.40±1.27	2.60±0.30	6.70	7.85±0.42	>100
4-t-BuBn (4k)	0.45±0.03	1.22±0.07	0.74±0.22	0.34±0.09	0.58±0.14	2.37±0.00	1.84±0.00
4-NO2Bn (4l)	0.38±0.13	0.64±0.01	0.81±0.23	0.18±0.22	0.26±0.34	2.49±0.32	1.28±0.71
4-FBn (4m)	1.08±0.01	1.34±0.19	2.60±6.12	1.77±4.10	2.38±5.38	8.82±1.14	3.31±0.00
3-ClBn (4n)	1.06±0.01	1.68±0.01	1.14±1.17	0.23±0.22	0.19±0.10	6.00±1.13	3.03±0.05
3-MeOBn (4o)	1.15±0.19	1.61±0.06	2.69±1.33	1.34±0.31	1.49±0.31	7.20±0.15	3.49±0.30
2-ClBn (4p)	1.30±0.07	0.99±0.08	2.10±0.52	3.20±1.37	3.70±0.85	6.66±5.44	>100
CH2C6H13 (4q)	0.61±0.00	1.29±0.16	0.99±0.24	0.24±0.32	0.30±0.26	3.13±0.14	1.20±0.06
Ph(CH2)2 (4r)	0.13±0.01	0.55±0.01	0.99±0.10	0.11±0.30	0.74±0.86	1.40±0.04	2.36±0.53
Ph(CH2)3 (4s)	1.73±0.05	1.65±0.03	NT	NT	NT	NT	NT

^aValues represent mean ± standard deviation for at least two separate experiments performed in triplicate.

^bCellular activities were determined with MTS/PMS cell viability assay.

^cCellular activities were determined with Promega CellTiter-Glo (CTG) luminescent assay.

^dCellular activities were determined with Sulforhodamine B Assay.